Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 19, 2019-- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials